Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 11, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

NEW YORK, Nov. 11, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
November 07, 2024 10:00 ET | Source: MiNK Therapeutics

MiNK’s iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

AgenT-797 Combination with Checkpoint Inhibitors and Bispecific Engagers Expands Anti-Cancer Benefit PRAME-TCR iNKT Overcomes Challenges from Conventional TCR-T Cells in Solid Cancers NEW YORK, Nov....
October 31, 2024 09:15 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

NEW YORK, Oct. 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT), a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT)...
October 08, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics (MiNK, NASDAQ: INKT) a clinical-stage company pioneering the development of allogeneic off-the-shelf, invariant natural killer T (iNKT)...
October 04, 2024 09:10 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

NEW YORK, Oct. 04, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
September 03, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
August 13, 2024 07:00 ET | Source: MiNK Therapeutics

MiNK Reports Second Quarter 2024 Results and Business Update

Expanded Access to AgenT-797 in Severe ARDS Reinforces Clinical Efficacy; Data Highlighted at ATS 2024 Annual MeetingPhase 2 Study in 2L Gastric Cancer Advances; Early Clinical Data to be Presented at...
August 01, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
July 31, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

NEW YORK, July 31, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
June 05, 2024 07:30 ET | Source: MiNK Therapeutics

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...